Special Episode: Daridorexant Approved for Insomnia
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Thomas Roth, PhD. [LISTEN TIME: 12 minutes]
A special episode of the NeurologyLive®
The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.
This episode, "Daridorexant Approved for Insomnia," features an exclusive interview with Thomas Roth, PhD, director, Sleep Disorders and Research Center, Henry Ford Hospital; professor of psychiatry, Wayne State University School of Medicine; and clinical professor of psychiatry, University of Michigan College of Medicine. Roth, who was an investigator in the clinical development studies of the newly approved Idorsia therapy, offered insight into the known efficacy and safety profiles, as well as some context to its potential impact on the therapeutic landscape of insomnia.
EPISODE BREAKDOWN
0:30 – Daridorexant (Quviviq; Idorsia) approved for insomnia
2:20 – Thomas Roth, PhD, with the clinical takeaways
4:30 – Efficacy data from Study 1 and Study 2
6:10 – Thomas Roth, PhD, on the efficacy profile
8:20 – Safety data from Study 1 and Study 2
9:00 – Thomas Roth, PhD, on the safety profile
REFERENCES
Idorsia receives US FDA approval of Quviviq (daridorexant) 25 and 50 mg for the treatment of adults with insomnia. News release. Idorsia. January 10, 2022. Accessed January 10, 2022. https://www.biospace.com/article/releases/idorsia-receives-us-fda-approval-of-quviviq-daridorexant-25-and-50-mg-for-the-treatment-of-adults-with-insomnia/?s=85
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
